Agomelatine: efficacy at each phase of antidepressant treatment.

CNS drugs

Volumn 23 Suppl 2, Issue , 2009, Pages 41-47

  Kennedy, Sidney H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; AGOMELATINE; ANTIDEPRESSANT AGENT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SEROTONIN 2C RECEPTOR;

CLINICAL TRIAL; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; REVIEW; SLEEP DISORDER;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C; RECURRENCE; SLEEP DISORDERS;

EID: 70350706600     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/11318660-000000000-00000     Document Type: Review

References (27)